Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK)
HKD 0.14
(1.41%)
HKD 0.14
(1.41%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 69.89 Million CNY | -54.55% |
| 2022 | 125.23 Million CNY | 64.73% |
| 2021 | 73.97 Million CNY | -3.51% |
| 2020 | 76.74 Million CNY | -24.24% |
| 2019 | 103.89 Million CNY | 17.32% |
| 2018 | 89.07 Million CNY | -2.87% |
| 2017 | 91.08 Million CNY | -19.14% |
| 2016 | 114.27 Million CNY | 44.44% |
| 2015 | 79.97 Million CNY | -17.55% |
| 2014 | 94.66 Million CNY | 30.9% |
| 2013 | 73.45 Million CNY | 6.94% |
| 2012 | 67.57 Million CNY | -0.87% |
| 2011 | 68.16 Million CNY | 1294.85% |
| 2010 | -10.18 Million CNY | 62.79% |
| 2009 | -15.33 Million CNY | 18.04% |
| 2008 | -18.7 Million CNY | -67.28% |
| 2007 | -11.18 Million CNY | 33.89% |
| 2006 | -16.91 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 32.98 Million CNY | 252.11% |
| 2024 Q2 | 30.3 Million CNY | -8.13% |
| 2023 Q2 | 14.58 Million CNY | -38.21% |
| 2023 FY | - CNY | -54.55% |
| 2023 Q3 | 19.46 Million CNY | 33.5% |
| 2023 Q1 | 23.59 Million CNY | -37.46% |
| 2023 Q4 | -34.58 Million CNY | -277.65% |
| 2022 FY | - CNY | 64.73% |
| 2022 Q4 | 37.73 Million CNY | 62.09% |
| 2022 Q1 | 15.73 Million CNY | 62.81% |
| 2022 Q2 | 11.9 Million CNY | -24.35% |
| 2022 Q3 | 23.27 Million CNY | 95.59% |
| 2021 Q1 | 22.01 Million CNY | 15.51% |
| 2021 Q4 | 9.66 Million CNY | -18.44% |
| 2021 Q3 | 11.84 Million CNY | 161.91% |
| 2021 FY | - CNY | -3.51% |
| 2021 Q2 | 4.52 Million CNY | -79.45% |
| 2020 Q4 | 19.05 Million CNY | 28.02% |
| 2020 FY | - CNY | -24.24% |
| 2020 Q1 | 11.75 Million CNY | -59.98% |
| 2020 Q2 | 7.23 Million CNY | -38.48% |
| 2020 Q3 | 14.88 Million CNY | 105.91% |
| 2019 Q3 | 24.95 Million CNY | 136.49% |
| 2019 Q2 | 10.55 Million CNY | -30.07% |
| 2019 FY | - CNY | 17.32% |
| 2019 Q1 | 15.08 Million CNY | -51.42% |
| 2019 Q4 | 29.36 Million CNY | 17.7% |
| 2018 Q1 | 18.95 Million CNY | -10.4% |
| 2018 FY | - CNY | -2.87% |
| 2018 Q4 | 31.05 Million CNY | 62.02% |
| 2018 Q3 | 19.16 Million CNY | 935.6% |
| 2018 Q2 | 1.85 Million CNY | -90.23% |
| 2017 FY | - CNY | -19.14% |
| 2017 Q3 | 17.86 Million CNY | 8.73% |
| 2017 Q2 | 16.43 Million CNY | -11.85% |
| 2017 Q1 | 18.64 Million CNY | -55.66% |
| 2017 Q4 | 21.15 Million CNY | 18.38% |
| 2016 Q1 | 14.68 Million CNY | 9.43% |
| 2016 Q2 | 17.28 Million CNY | 17.73% |
| 2016 Q3 | 18.73 Million CNY | 8.4% |
| 2016 FY | - CNY | 44.44% |
| 2016 Q4 | 42.04 Million CNY | 124.4% |
| 2015 Q1 | 21.03 Million CNY | 162.0% |
| 2015 Q2 | 10.48 Million CNY | -50.17% |
| 2015 FY | - CNY | -17.55% |
| 2015 Q4 | 13.41 Million CNY | 25.65% |
| 2015 Q3 | 10.67 Million CNY | 1.87% |
| 2014 FY | - CNY | 30.9% |
| 2014 Q2 | 22.94 Million CNY | -1.85% |
| 2014 Q4 | 8.02 Million CNY | -53.07% |
| 2014 Q3 | 17.1 Million CNY | -25.44% |
| 2014 Q1 | 23.37 Million CNY | 2040.08% |
| 2013 FY | - CNY | 6.94% |
| 2013 Q4 | -1.2 Million CNY | -110.54% |
| 2013 Q1 | 23.98 Million CNY | 420.0% |
| 2013 Q3 | 11.43 Million CNY | -28.46% |
| 2013 Q2 | 15.98 Million CNY | -33.36% |
| 2012 Q2 | 26.06 Million CNY | 30.33% |
| 2012 Q4 | -7.49 Million CNY | -186.86% |
| 2012 Q3 | 8.62 Million CNY | -66.89% |
| 2012 Q1 | 19.99 Million CNY | 221.27% |
| 2012 FY | - CNY | -0.87% |
| 2011 Q3 | 28.91 Million CNY | 90.68% |
| 2011 FY | - CNY | 1294.85% |
| 2011 Q1 | 12.78 Million CNY | 220.93% |
| 2011 Q2 | 15.16 Million CNY | 18.6% |
| 2011 Q4 | -16.49 Million CNY | -157.03% |
| 2010 Q1 | -5.19 Million CNY | 38.77% |
| 2010 FY | - CNY | 62.79% |
| 2010 Q4 | -10.57 Million CNY | -285.41% |
| 2010 Q3 | 5.7 Million CNY | 211.43% |
| 2010 Q2 | -5.11 Million CNY | 1.44% |
| 2009 Q2 | -6.04 Million CNY | 0.0% |
| 2009 Q3 | -8.72 Million CNY | -44.16% |
| 2009 FY | - CNY | 18.04% |
| 2009 Q4 | -8.48 Million CNY | 2.74% |
| 2008 FY | - CNY | -67.28% |
| 2007 FY | - CNY | 33.89% |
| 2006 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 53.529% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 97.644% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 153.962% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | 38.582% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 239.147% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | 36.358% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 83.294% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | 8.796% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 367.079% |
| SSY Group Limited | 2.11 Billion HKD | 96.695% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 65.805% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 83.743% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.547% |